phospho-Smad3 (Thr179) Polyclonal Antibody, Cy5.5 Conjugated
Applications
Reactivity
Predicted Reactivity
| Overview | |
| Catalog # | bs-19452R-Cy5.5 |
| Product Name | phospho-Smad3 (Thr179) Polyclonal Antibody, Cy5.5 Conjugated |
| Applications |
WB
FCM
IF(IHC-P)
IF(IHC-F)
IF(ICC)
|
| Reactivity | Human, Mouse, Rat |
| Predicted Reactivity | Dog, Cow, Sheep, Pig, Horse |
| Specifications | |
| Conjugation | Cy5.5 |
| Host | Rabbit |
| Source | KLH conjugated synthesised phosphopeptide derived from human Smad3 around the phosphorylation site of Thr179 |
| Modification Site | Thr179 |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein A. |
| Storage Buffer | Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target | |
| Gene ID | 4088 |
| Swiss Prot | P84022 |
| Subcellular location | Cytoplasm, Nucleus |
| Synonyms | Mothers against decapentaplegic homolog 3; SMAD3; JV15-2 |
| Background | Receptor-regulated SMAD (R-SMAD) that is an intracellular signal transducer and transcriptional modulator activated by TGF-beta (transforming growth factor) and activin type 1 receptor kinases. Binds the TRE element in the promoter region of many genes that are regulated by TGF-beta and, on formation of the SMAD3/SMAD4 complex, activates transcription. Also can form a SMAD3/SMAD4/JUN/FOS complex at the AP-1/SMAD site to regulate TGF-beta-mediated transcription. Has an inhibitory effect on wound healing probably by modulating both growth and migration of primary keratinocytes and by altering the TGF-mediated chemotaxis of monocytes. This effect on wound healing appears to be hormone-sensitive. Regulator of chondrogenesis and osteogenesis and inhibits early healing of bone fractures. Positively regulates PDPK1 kinase activity by stimulating its dissociation from the 14-3-3 protein YWHAQ which acts as a negative regulator. |
| Application Dilution | |
| WB | 1:300-5000 |
| FCM | 1:20-100 |
| IF(IHC-P) | 1:50-200 |
| IF(IHC-F) | 1:50-200 |
| IF(ICC) | 1:50-200 |
Frequently asked questions
Which applications is phospho-Smad3 (Thr179) Polyclonal Antibody, Cy5.5 Conjugated (BS-19452R-CY5-5) validated for, and at what dilution?
BS-19452R-CY5-5 is validated for WB (1:300-5000); FCM (1:20-100); IF(IHC-P) (1:50-200); IF(IHC-F) (1:50-200); IF(ICC) (1:50-200). These are recommended starting dilutions; optimal dilutions should be determined by the end user.
Which species does phospho-Smad3 (Thr179) Polyclonal Antibody, Cy5.5 Conjugated (BS-19452R-CY5-5) react with?
Tested reactivity: Human, Mouse, Rat. Predicted reactivity (expected from sequence homology but not yet tested): Dog, Cow, Sheep, Pig, Horse.
How should BS-19452R-CY5-5 be stored?
Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. Storage buffer: Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
What immunogen was used to raise phospho-Smad3 (Thr179) Polyclonal Antibody, Cy5.5 Conjugated (BS-19452R-CY5-5)?
KLH conjugated synthesised phosphopeptide derived from human Smad3 around the phosphorylation site of Thr179
What are the excitation and emission wavelengths of the Cy5.5 conjugate (BS-19452R-CY5-5)?
Cy5.5 on BS-19452R-CY5-5: excitation / emission 675nm/694nm.